A new clinical study, sponsored by Ataturk University, investigates the efficacy of combining pericapsular nerve group (PENG) block with superior cluneal and superior gluteal nerve blocks for patients undergoing hip surgery. This marks an important inquiry into optimizing regional analgesia techniques for better pain control and recovery outcomes.
The clinical trial focuses on conditions such as hip osteoarthritis, osteonecrosis of the femoral head, avascular necrosis of the femur head, and hip dysplasia. Physicians and regulatory teams involved in hip surgery and pain management are encouraged to follow ongoing updates from this study.
In this article:
- What does the study investigate?
- How are the interventions compared?
- Who should care?
- FAQs
- Conclusion
- Disclaimer
- Where to learn more?
What does the study investigate?
The study, enrolling participants by invitation only, aims to analyze the impact of combining PENG block with other nerve blocks on pain relief and recovery in hip surgical patients. The primary focus is whether this combined approach outperforms the PENG block alone in terms of analgesic efficacy and safety parameters.
Conditions targeted include hip osteoarthritis, hip joint dysplasia, and femoral head necrosis, which are common indications for hip surgeries. This could provide valuable insights for anesthesiologists and regulatory experts focusing on advanced pain management protocols.
How are the interventions compared?
The trial uses two distinct interventions:
- 15 mL of bupivacaine HCl 0.25% for PENG block alone
- 20 mL of bupivacaine 0.25% when combining PENG block with superior cluneal and superior gluteal nerve blocks
The differing volumes and nerve block strategies are carefully studied to assess their relative benefits for pain control while maintaining a focus on patient safety and minimizing side effects. Bupivacaine, cited for its reliability as a local anesthetic, serves as the drug of choice.
Regulatory teams should note that this study aligns with MDR Annex XIV documentation standards, helping establish reproducible clinical safety and performance data.
Who should care?
Clinical, quality, and regulatory teams focused on hip surgery outcomes should closely monitor these findings. Effective pain management directly influences patient satisfaction, recovery timelines, and perioperative care costs. For medical device manufacturers developing nerve block tools, this research underscores the importance of evidence-based improvements to procedural technology.
This study is also significant for hospitals designing post-operative pain protocols. Insights from the trial can guide decisions around anesthetic volume and combination strategies.
FAQs
1. Who is sponsoring this study?
The clinical trial is sponsored by Ataturk University.
2. What conditions are covered?
Target conditions include hip osteoarthritis, osteonecrosis of the femoral head, avascular necrosis of the femur head, and hip dysplasia.
3. What drugs are being used?
Bupivacaine HCl 0.25%, with volumes of 15 mL and 20 mL depending on the intervention.
Conclusion
This clinical study brings valuable insights into combining PENG blocks with superior cluneal and superior gluteal nerve blocks for improved pain management in hip surgeries. Teams across perioperative care, product design, and regulatory compliance are advised to consider its implications for advancing regional anesthesia practices.
Disclaimer
This article is for informational purposes only. It does not constitute legal advice or clinical guidance. Consult the official ClinicalTrials.gov entry for complete and verified data.
Where to learn more?
For full information about the announcement, see the link below:
https://clinicaltrials.gov/study/NCT07255768?term=medical+device